These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 7690418)

  • 21. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    Moore JP; McCutchan FE; Poon SW; Mascola J; Liu J; Cao Y; Ho DD
    J Virol; 1994 Dec; 68(12):8350-64. PubMed ID: 7525988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
    Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR
    J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro.
    Cordell J; Moore JP; Dean CJ; Klasse PJ; Weiss RA; McKeating JA
    Virology; 1991 Nov; 185(1):72-9. PubMed ID: 1718090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
    Gorny MK; Moore JP; Conley AJ; Karwowska S; Sodroski J; Williams C; Burda S; Boots LJ; Zolla-Pazner S
    J Virol; 1994 Dec; 68(12):8312-20. PubMed ID: 7525987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
    J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.
    Pinter A; Honnen WJ; Kayman SC; Trochev O; Wu Z
    Vaccine; 1998 Nov; 16(19):1803-11. PubMed ID: 9795384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralization epitopes of the HIV-1 primary isolate DH012.
    Zhu C; Matthews TJ; Chen CH
    Vaccine; 2003 Jul; 21(23):3301-6. PubMed ID: 12804861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    Earl PL; Broder CC; Long D; Lee SA; Peterson J; Chakrabarti S; Doms RW; Moss B
    J Virol; 1994 May; 68(5):3015-26. PubMed ID: 7512157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
    Moore JP; Thali M; Jameson BA; Vignaux F; Lewis GK; Poon SW; Charles M; Fung MS; Sun B; Durda PJ
    J Virol; 1993 Aug; 67(8):4785-96. PubMed ID: 7687303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
    Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
    Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    Moore JP; Cao Y; Qing L; Sattentau QJ; Pyati J; Koduri R; Robinson J; Barbas CF; Burton DR; Ho DD
    J Virol; 1995 Jan; 69(1):101-9. PubMed ID: 7527081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.
    McKeating JA; Thali M; Furman C; Karwowska S; Gorny MK; Cordell J; Zolla-Pazner S; Sodroski J; Weiss RA
    Virology; 1992 Sep; 190(1):134-42. PubMed ID: 1382339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.
    Jeffs SA; Gorny MK; Williams C; Revesz K; Volsky B; Burda S; Wang XH; Bandres J; Zolla-Pazner S; Holmes H
    Immunol Lett; 2001 Dec; 79(3):209-13. PubMed ID: 11600200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
    J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.